Tag: diabetes mellitus

  Chef Michel Nischan has won the prestigious James Beard Award four times, written cookbooks, and launched a restaurant with the late actor Paul Newman. But the motto on his website reveals what he’s really about: “Changing the world through food.” As co-founder and chairman of Wholesome Wave, a nonprofit founded in 2007 to solve

Incorporation of a nonintensive fitness intervention for women with obesity into a standard fertility treatment program could be cost-effective, a new analysis finds. Financial data for the Canadian Fit-for-Fertility program were presented March 20 at the virtual ENDO 2021: The Endocrine Society Annual Meeting by Matea Belan, PhD, of the division of endocrinology at the University

Incorporation of a nonintensive fitness intervention for women with obesity into a standard fertility treatment program could be cost-effective, a new analysis finds. Financial data for the Canadian Fit-for-Fertility program were presented March 20 at the virtual ENDO 2021: The Endocrine Society Annual Meeting by Matea Belan, PhD, of the division of endocrinology at the University

Intravitreal injections with aflibercept (Eylea) don’t improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk for center-involved diabetic macular edema and proliferative diabetic retinopathy, however, said Adam R. Glassman, MS, principal investigator of the DRCR Retina Network Coordinating Center, Tampa, Florida. “Some clinicians may decide

The high cost of a sedentary lifestyle just became a bit more evident ― a new global study shows that inactivity drives up to 8% of noncommunicable diseases and mortality. Physical inactivity, defined as engaging in less than 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity per week, caused 7.2% (95% CI,

A 2.4-mg weekly injection of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide led to a clinically meaningful 5% loss in weight for roughly two thirds of patients with both overweight/obesity and type 2 diabetes, researchers report. These findings from the Semaglutide Treatment Effect in People With Obesity 2 (STEP 2) trial, one of four phase